M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 20.05.2020 | 09:00

M1 Kliniken AG: Publishes consolidated financial statements 2019 - encouraging resumption of patient treatments - shortened notice periods for Annual General Meeting on 09 July 2020

DGAP-News: M1 Kliniken AG / Key word(s): Annual Results/Market Report
20.05.2020 / 09:00
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG publishes consolidated financial statements 2019 - encouraging resumption of patient treatments - shortened notice periods for Annual General Meeting on 09 July 2020

- Consolidated sales +18 % to 77.2 million euros; consolidated net income +47 % to 9.7 million euros

- Positive development after resumption of patient treatment

- Annual General Meeting still scheduled for 9.07.2020 - shortened deadlines

Berlin, 20.05.2020 - M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its consolidated financial statements for 2019. The M1 Group has increased its consolidated revenue by 18 % to EUR 77.2 million (previous year: EUR 65.2 million) in the financial year 2019. The consolidated net profit for the year increased by 47 % to 9.7 million euros (previous year: 6.6 million euros). The consolidated financial statements for 2019 were adopted by the Supervisory Board in its meeting on 20 April 2020.

The 2019 annual report of M1 Kliniken AG available for download: www.m1-kliniken.de

After the M1 Group had to temporarily close its practices and clinics in Germany and abroad on 23 March 2020, the majority of sites have now been reopened on the basis of a strict hygiene concept. Despite extended treatment intervals, a turnover level comparable to the "pre-corona business volume" has been achieved in the first week. In addition, schedules are almost completely booked out for a period of several weeks. M1 therefore assumes that the closure period and other effects of the corona pandemic will not have a long-term and sustainable impact on the Group's business model.

According to current planning, the Annual General Meeting of M1 Kliniken AG is still scheduled to take place on 9 July 2020. The Company is monitoring the development of the pandemic in order to decide whether to hold a 'classical' meeting or a virtual general meeting. For this purpose, the Company will work with shortened notice periods. The invitation to the Annual General Meeting will probably be published in the Federal Gazette ("Bundesanzeiger") towards the end of week 24.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brand M1 Med Beauty beauty medical treatments are currently offered at more than 35 locations. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with its international expansion and is currently active in Austria, Switzerland, the Netherlands, UK and Australia. The Group is now also growing in other European countries. It markets high-quality products to private customers, doctors, pharmacies and wholesalers under the M1 Select and M1 Aesthetics brands. www.m1-kliniken.de

Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


20.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Covestro AG: Covestro übernimmt den Geschäftsbereich Resins & Functional Materials (RFM) von DSM

30. September 2020, 08:01

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

30. September 2020